NICE prepares to reject four kidney cancer drugs
This article was originally published in Scrip
Executive Summary
Four products used in the treatment of advanced and/or metastatic renal cell carcinoma have been tentatively rejected byNICE, which assesses the clinical and cost-effectiveness of technology for the national health service in England and Wales. Draft guidance on bevacizumab (Roche's Avastin), sorafenib (Bayer's Nexavar), sunitinib (Pfizer's Sutent) and temsirolimus (Wyeth's Torisel) says the drugs do not represent the best use of NHS resources